The use of probiotics in gastrointestinal diseases

Mediterranean Journal of Nutrition and Metabolism

Volumn 3, Issue 2, 2010, Pages 105-113

  Pagliaro, Giacomo ^a   Battino, Maurizio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Clinical effectiveness; Clinical trials; Dysbiosis; Gastrointestinal disease; Probiotics; Safety

Indexed keywords

PROBIOTIC AGENT;

BACTERIAL COLONIZATION; BACTERIAL STRAIN; BIFIDOBACTERIUM; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSBIOSIS; ENTERITIS; ENTEROCOCCUS FAECIUM; GASTROINTESTINAL DISEASE; HELICOBACTER PYLORI; HUMAN; ILEITIS; IRRITABLE COLON; LACTOBACILLUS; NECROTIZING ENTEROCOLITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS SALIVARIUS; T LYMPHOCYTE;

HELICOBACTER PYLORI;

EID: 77957195120     PISSN: 1973798X     EISSN: 19737998     Source Type: Journal    
DOI: 10.1007/s12349-010-0008-9     Document Type: Review

References (81)

1. C Maldonado Galdeano A de Le Moreno Blanc G Vinderola, et al. 2007 Proposed model: mechanisms of immunomodulation induced by probiotic bacteria Clin Vac Imm 14 485 492 10.1128/CVI.00406-06
2. E Metchnikoff 1910 Etudes sur la flore intestinale Deuxieme memoire Ann Inst Pasteur Paris 24 755 770
3. R Fuller 1989 Probiotics in man and animals J Appl Bacteriol 66 365 369
4. AA VV (2002) Guidelines for the evaluation of probiotics in food. FAO/WHO, London
5. GV Zuccotti F Meneghin C Raimondi, et al. 2008 Probiotics in clinical practice: an overview J Inter Med Res 36 1 1A 53A
6. N Inohara Y Ogura A Fontalba, et al. 2003 Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease J Biol Chem 278 5509 5512 10.1074/jbc.C200673200 (Pubitemid 36800790)
7. S Maeda LC Hsu H Liu, et al. 2005 NOD2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing Science 307 734 738 10.1126/science.1103685 (Pubitemid 40194645)
8. LW Lamps KT Madhusudhan JM Havens, et al. 2003 Pathogenic Yersinia DNA is detected in bowel and mesenteric lymph-nodes from patients with Crohn's disease Am J Surg Pathol 27 220 227 10.1097/00000478-200302000-00011 (Pubitemid 36152232)
9. SE Girardin IG Boneca J Viala, et al. 2003 NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection J Biol Chem 278 8869 8872 10.1074/jbc.C200651200 (Pubitemid 36800360)
10. A Allen DA Hutton JP Pearson 1998 The MUC2 gene product: a human intestinal mucin Int J Biochem Cell Biol 30 7 797 801 10.1016/S1357-2725(98) 00028-4 (Pubitemid 28352741)
11. JC Byrd RS Bresalier 2004 Mucins and mucin binding proteins in colorectal cancer Canc Met Rev 23 1-2 77 99 10.1023/A:1025815113599 (Pubitemid 38221597)
12. T Watanabe A Kitani PJ Murray, et al. 2004 NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses Nat Immunol 5 800 808 10.1038/ni1092 (Pubitemid 39172973)
13. C Neut P Bulois P Desreumaux, et al. 2002 Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease Am J Gastroenterol 97 939 946 10.1111/j.1572-0241.2002.05613.x
14. LV McFarland 2008 Antibiotic-associated diarrhea: epidemiology, trends and treatment Fut Microb 5 3 563 578 10.2217/17460913.3.5.563
15. F Barbut JC Petit 2001 Epidemiology of Clostridium difficile-associated infections Clin Microbiol Infect 7 405 410 10.1046/j.1198-743x.2001.00289.x (Pubitemid 34960330)
16. A Sullivan CE Nord 2005 Probiotics and gastrointestinal diseases Nord J Inter Med 257 78 92 10.1111/j.1365-2796.2004.01410.x (Pubitemid 40129129)
17. LV McFarland 2006 Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease Am J Gastroenterol 101 812 822 10.1111/j.1572-0241.2006.00465.x
18. T Arvola K Laiho S Torkkeli, et al. 1999 Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study Pediatrics 104 e64 10.1542/peds.104.5.e64
19. RD Rolfe 2000 The role of probiotic cultures in the control of gastrointestinal health J Nutr 130 396S 402S
20. I Castagliuolo MF Riegler L Valenick, et al. 1999 Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa Infect Immun 67 302 307
21. Gareau MG, Silva MA, Perdue MH (2008) Pathophysiological mechanisms of stress-induced intestinal damage. Cur Mol Med 8(4):274-281(8)
22. D Damaskos G Kolios 2007 Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope' Br J Clin Pharmacol 65 4 453 467 10.1111/j.1365-2125.2008.03096.x
23. MA Gassull 2006 Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease Aliment Pharmacol Ther 24 3 90 95 10.1111/j.1365-2036.2006.03067.x (Pubitemid 44326427)
24. Schultz M, Lindström AL (2008) Rationale for probiotic treatment strategies in inflammatory bowel disease. Exp Rev Gastroenter Hepat 2(3):337-355(19)
25. G De Hertogh J Aerssens KP Geboes, et al. 2008 Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease World J Gastroenetrol 14 6 845 852 10.3748/wjg.14.845 (Pubitemid 351325023)
26. HJ Van Kruiningen M Joossens S Vermeire, et al. 2005 Environmental factors in familial Crohn's disease in Belgium Inflamm Bowel Dis 11 360 365 10.1097/01.MIB.0000158536.31557.90 (Pubitemid 40542267)
27. K Geboes 2005 Appendiceal function and dysfunction: what are the implications for inflammatory bowel disease? Nat Clin Pract Gastroenterol Hepatol 2 338 339 10.1038/ncpgasthep0238 (Pubitemid 41655565)
28. Parkes G, Brostoff J, Whelan K et al. (2008) Gastrointestinal microbiota bowel syndrome: their role in its pathogenesis and treatment. Am J of Gastroenterol 103(6):1557-1567(11)
29. Heilpern D, Szilagyi A (2008) Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, prebiotics and synbiotics. Rev Rec Clin Trials 3(3):167-184(18)
30. MA Zocco L Zileri Dal Verme A Armuzzi, et al. 2003 Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn's disease Gastroenterol 124 A201 10.1016/S0016-5085(03)81006-5
31. Rolfe VE, Fortun PJ, Hawkey CJ et al. (2006) Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev CD004826
32. EV Loftus 2004 Clinical epidemiology of inflammatory bowel diseases: incidence, prevalence and environmental influences Gastroenterol 126 1504 1517 10.1053/j.gastro.2004.01.063 (Pubitemid 38649869)
33. RB Sartor 2004 Therapeutic manipulation of the enteric microflora in inflammatory bowel disease: antibiotics, probiotics and prebiotics Gastroenterol 125 1620 1633 10.1053/j.gastro.2004.03.024 (Pubitemid 38649878)
34. KL Madsen JS Doyle LD Jewell, et al. 1999 Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice Gastroenterol 116 1107 1114 10.1016/S0016-5085(99)70013-2 (Pubitemid 29203020)
35. H Ishikawa I Akedo Y Umesaki, et al. 2003 Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis J Am Coll Nutr 22 56 63
36. R Bibiloni RN Fedorak GW Tannock, et al. 2005 VSL#3 probiotic mixture induces remission in patients with active ulcerative colitis Am J Gastroenterol 100 1539 1546 10.1111/j.1572-0241.2005.41794.x (Pubitemid 41032360)
37. E Furrie S Macfarlane A Kennedy, et al. 2005 Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial Gut 54 242 249 10.1136/gut.2004.044834 (Pubitemid 40139241)
38. M Guslandi P Giollo PA Testoni 2003 A pilot trialof Saccharomyces boulardii in ulcerative colitis Eur J Gastroenterol Hepatol 15 697 698 10.1097/00042737-200306000-00017 (Pubitemid 36688235)
39. K Kato S Mizuno Y Umesaki, et al. 2004 Randomized placebo-controlled trial assessing the effect of bifidobacteria fermented milk on active ulcerative colitis Aliment Pharmacol Ther 20 1133 1141 10.1111/j.1365-2036.2004.02268.x (Pubitemid 39657947)
40. DS Pardi G D'Haens B Shen, et al. 2009 Clinical guidelines for the management of pouchitis Inflamm Bowel Dis 15 9 1424 1431 10.1002/ibd.21039
41. P Gionchetti F Rizzello C Morselli, et al. 2007 High-dose probiotics for the treatment of active pouchitis Dis Colon Rectum 50 2075 2082 10.1007/s10350-007-9068-4 discussion 2082-2084
42. JG Ruseler-van Embden WR Schouten LM van Lieshout 1994 Pouchitis: result of microbial imbalance? Gut 35 658 664 10.1136/gut.35.5.658
43. P Rutgeerts M Hiele K Geboes, et al. 1995 Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection Gastroenterology 108 1617 1621 10.1016/0016-5085(95)90121-3
44. Gosselink MP, Schouten WR, Lieshout LMC et al. (2004) Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 47(6):876-884 (9)
45. AP Hunghin PJ Whorwell J Tack, et al. 2003 The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects Aliment Pharmacol Ther 17 5 643 650 10.1046/j.1365-2036.2003.01456.x (Pubitemid 36418887)
46. Casiday RE, Hungin APS, Cornford CS et al. (2009) Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology. Fam Pract 26(1):40-47(8)
47. M Guslandi 2007 Probiotic agent in the treatment of irritable bowel syndrome J Int Med Res 35 583 589
48. HC Lin 2004 Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome JAMA 292 852 858 10.1001/jama.292.7.852 (Pubitemid 39079672)
49. N Arebi S Gurmany D Bullas, et al. 2008 Review article: the psychoneuroimmunology of irritable bowel syndrome-an exploration of interactions between psychological, neurological and immunological observations Aliment Pharmacol Ther 28 830 840 10.1111/j.1365-2036.2008.03801.x
50. EF Verdu P Bercik M Verma-Gandhu 2006 Specific probiotic therapy attenuates antibiotic-induced visceral hypersensitivity in mice Gut 55 2 182 190 10.1136/gut.2005.066100 (Pubitemid 43117275)
51. SK Mazmanian JL Round DL Kasper 2008 A microbial symbiosis factor prevents intestinal inflammatory disease Nature May 29;453 7195 620 625 10.1038/nature07008 (Pubitemid 351769307)
52. L O'Mahony J McCarthy P Kelly, et al. 2005 A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom response and relationship to cytokines profiles Gastroenterology 128 541 550 10.1053/j.gastro.2004.11.050 (Pubitemid 40585355)
53. PJ Whorwell L Altringer J Morel, et al. 2006 Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome Am J Gastroenterol 101 1581 1590 10.1111/j.1572-0241.2006.00734.x (Pubitemid 43980633)
54. Sen S, Mullan MM, Parker TJ, Woolner JT et al. (2002) Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 47:2615-20
55. AJ Stagg AL Hart SC Knight, et al. 2004 Microbial-gut interactions in health and disease. Interactions between dendritic cells and bacteria in the regulation of intestinal immunity Best Pract Res Clin Gastroenterol 18 255 270 10.1016/j.bpg.2003.10.004 (Pubitemid 38444129)
56. AL Hart K Lammers P Brigidi, et al. 2004 Modulation of human dendritic cell phenotype and function by probiotic bacteria Gut 53 1602 1609 10.1136/gut.2003.037325 (Pubitemid 39434103)
57. Kimoto-Nira H, Suzuki C, Kobayashi M et al. (2008) Different Growth Media Alter the Induction of Interleukin 12 by a Lactococcus lactis Strain. J Food Prot 71(10):2124-2128(5)
58. MA Storr B Yuce CN Andrews, et al. 2008 The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome Neurogastroenterol Motil 20 857 868 10.1111/j.1365-2982.2008.01175.x (Pubitemid 352022722)
59. J Zeng YQ Li XL Zuo, et al. 2008 Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowel syndrome Aliment Pharmacol Ther 15;28 8 994 1002 10.1111/j.1365-2036.2008.03818.x
60. V Mai JG Morris Jr 2004 Colonic bacterial flora: changing understandings in the molecular age J Nutr 134 459 464
61. M Rajilic′-Stojanovic′ H Smidt, et al. 2007 Diversity of the human gastrointestinal tract microbiota revisited Environ Microbiol 9 9 2125 2136 10.1111/j.1462-2920.2007.01369.x (Pubitemid 47222128)
62. F Guarner JR Malagelada 2003 Gut flora in health and disease Lancet 361 512 519 10.1016/S0140-6736(03)12489-0 (Pubitemid 36173720)
63. P Louis KP Scott SH Duncan, et al. 2007 Understanding the effects of diet on bacterial metabolism in the large intestine J App Microb 102 1197 1208 10.1111/j.1365-2672.2007.03322.x (Pubitemid 46633434)
64. HJ Flint SH Duncan KP Scott, et al. 2007 Interactions and competition within the microbial community of the human colon: links between diet and health Environ Microb 9 5 1101 1111 10.1111/j.1462-2920.2007.01281.x (Pubitemid 46697267)
65. Ling-nan B, Mei-Hwei C, Yen-Hsuan N et al. (2007) Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediat Int 49(4):485-490(6)
66. S Zar MJ Benson D Kumar 2002 Bloating in functional bowel disorders Alim Pharm Ther 16 11 1867 1876 10.1046/j.1365-2036.2002.01369.x (Pubitemid 35253002)
67. Isil F, Ayse K, Emine Y et al. (2009) Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. Mycoses 52(1):29-34(6)
68. M Gotteland O Brunser S Cruchet 2006 Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 23 1077 1086 10.1111/j.1365-2036.2006.02868.x (Pubitemid 43779346)
69. PD Midolo JR Lambert R Hull, et al. 1995 In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria J Appl Bacteriol 79 475 479
70. Kim MN, Kim N, Lee SH, et al. (2008) The effects of probiotics on PPI-Triple therapy for Helicobacter pylori eradication. Helicobacter 13(4):261-268(8)
71. Francavilla R, Lionetti E, Castellaneta SP et al. (2008) Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13(2):127-134(8)
72. Thompson AM, Bizzarro MJ (2008) Necrotizing enterocolitis in newborns: pathogenesis, prevention and management. Drugs 68(9):1227-1238(12)
73. EC Claud WA Walker 2001 Hypothesis: inappropriate colonization of the premature intestine can cause neonatal necrotizing enterocolitis FASEB J 15 1398 1403 10.1096/fj.00-0833hyp (Pubitemid 32531817)
74. C Hoy MR Millar P MacKay, et al. 1990 Quantitative changes in faecal microflora preceding necrotising enterocolitis in premature neonates Arch Dis Child 65 10 1057 1059 10.1136/adc.65.10-Spec-No.1057
75. MR Millar P MacKay M Levene, et al. 1992 Enterobacteriaceae and neonatal necrotising enterocolitis Arch Dis Child 67 1 53 56 10.1136/adc.67.1-Spec-No.53
76. IH Gewolb RS Schwalbe VL Taciak, et al. 1999 Stool microflora in extremely low birthweight infants Arch Dis Child Fetal Neonatal Ed 80 3 F167 F173 10.1136/fn.80.3.F167
77. K Hatakka E Savilahti A Ponka, et al. 2001 Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial BM J 322 7298 1327 10.1136/bmj.322.7298. 1327
78. Koteyko N (2009) 'I am a very happy, lucky lady, and I am full of Vitality!' Analysis of promotional strategies on the websites of probiotic yoghurt producers. Critical Disc Stud 6(2):111-125(15)
79. Bahna SL (2008) Reflections on current food allergy controversies: Specific IgE test application, patch testing, eosinophilic esophagitis, and probiotics. Aller Asth Proc 29(5):447-452(6)
80. Wassenaar TM, Klein G (2008) Safety aspects and implications of regulation of probiotic bacteria in food and food supplements. J Food Prot 71(8):1734-1741(8)
81. Basselink MG, van Santvoort HC, Buskens E et al. (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo controlled trial. Lancet 23;371(9613):651-9